Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy for Papulopustular Rosacea

NCT02075671
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
Aminolevulinic acid topical solution 20%, Blu-U Light Therapy, Placebo vehicle only
Drug · Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03569371
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 30, 2026, 5:49 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Novel Thermal Imaging Technique for Breast Screening

NCT05650086
View directory record Official record
Conditions
Breast Cancer
Interventions
Thermalytix
Device
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

NCT00057941
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

NCT01421966
View directory record Official record
Conditions
Lower Extremity Chronic Ulcers in Diabetics
Interventions
CureXcell®, Sham injection
Biological
Lead sponsor
Macrocure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 30, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

NCT00987545
View directory record Official record
Conditions
Keloids
Interventions
QAX576, QAX576 placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Paramus, New Jersey • Rochester, New York • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

NCT06303570
View directory record Official record
Conditions
Dercum's Disease
Interventions
CBL-514 injection, 0.9% Sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05914805
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

NCT01588522
View directory record Official record
Conditions
Chemotherapy-Induced Alopecia
Interventions
Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL, Compound 31543 Calcitriol 40 μg/mL, Compound 31543 Calcitriol 60 ug/mL, Compound 31543 Calcitriol 80 μg/mL
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 30, 2026, 5:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women

NCT01817231
View directory record Official record
Conditions
Breast Cancer, Vitamin D Deficiency
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Diet Effect on Cancer Treatment Outcome

NCT05410002
View directory record Official record
Conditions
Cancer Breast, Cancer Prostate
Interventions
Dietary Supplement: N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

NCT02165345
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 30, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 30, 2026, 5:49 PM EDT
Completed No phase listed Observational

Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

NCT06096077
View directory record Official record
Conditions
Angioedema
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 30, 2026, 5:49 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345
View directory record Official record
Conditions
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
Interventions
LTT462
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 5:49 PM EDT
Not listed Phase 1 Interventional

A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
View directory record Official record
Conditions
Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
Interventions
MM-310
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer

NCT01844479
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot
Interventions
diabetic foot orthotic, Standard innersole
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 30, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 30, 2026, 5:49 PM EDT